US 10,376,487 B2
Method of treatment
Marlene Michelle Dressman, Germantown, MD (US); Mihael H. Polymeropoulos, Potomac, MD (US); and Paolo Baroldi, Potomac, MD (US)
Assigned to Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed by Vanda Pharmaceuticals, Inc., Washington, DC (US)
Filed on Oct. 10, 2014, as Appl. No. 14/511,669.
Claims priority of provisional application 61/927,465, filed on Jan. 14, 2014.
Claims priority of provisional application 61/903,354, filed on Nov. 12, 2013.
Prior Publication US 2015/0196527 A1, Jul. 16, 2015
Prior Publication US 2017/0087122 A9, Mar. 30, 2017
Int. Cl. A61K 31/343 (2006.01)
CPC A61K 31/343 (2013.01) 20 Claims
 
1. A method of treating a human patient suffering from a circadian rhythm disorder or a sleep disorder that comprises orally administering to the patient an effective dose of tasimelteon without food, wherein the effective dose is 20 mg/d.